Patient selection for TAVI in 2014: Is there a justification for treating low- or intermediate-risk patients? the surgeon's view

The introduction of transcatheter aortic valve implantation (TAVI) has revolutionised the treatment of patients with symptomatic severe aortic valve stenosis (AS). In extreme and high-risk patients, randomised studies have shown the benefit of this new therapy. However, there are still a lot of unknowns, and the question has arisen whether it is justified to expand the indication of TAVI to other patient groups, especially intermediate-or even low-risk patients.

• View at Publisher
• View at Pubmed
• View at Scopus